GazianoT, ReddyKS, PaccaudF. Chapter 33 Cardiovascular Disease. In: JamisonDT, BremanJG, MeashamAR, editors. Disease Control Priorities in Developing Countries 2nd edition. Washington (DC): The International Bank for Reconstruction and Development/The World Bank;, 2006.
2.
LibbyP, RidkerPM, HanssonGK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol2009; 54: 2129–38.
3.
AbbasiSH, BoroumandMA. Expanded network of inflammatory markers of atherogenesis: where are we now?Open Cardiovasc Med J2010; 4: 38–44.
4.
MisraDP, AgarwalV. CANTOS – is selective targeting of inflammation in atherosclerosis enough?J R Coll Physicians Edinb2018; 48: 246–7.
5.
ChanES, CronsteinBN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res2002; 4: 266–73.
6.
RidkerPM, MacFadyenJG, EverettBM. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial. Lancet2018; 391: 319–28.
7.
RidkerPM, LibbyP, MacFadyenJG. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J2018; 39: 3499–507.
8.
ChoiHK, HernánMA, SeegerJD. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet2002; 359: 1173–7.
9.
WestlakeSL, ColebatchAN, BairdJ. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford)2010; 49: 295–307.
10.
RidkerPM, EverettBM, PradhanA. CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med2019; 21; 380: 752–62.
11.
NaranjoA, SokkaT, DescalzoMA. QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther2008; 10: R30.
12.
ProdanovichS, MaF, TaylorJR. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol2005; 52: 262–7.
